Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Aug 30;9(11):1298–1315. doi: 10.1158/2326-6066.CIR-21-0543

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

©2021 The Authors; Published by the American Association for Cancer Research

This open access article is distributed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) license.

PMC Copyright notice

Figure 7. Low ATFIP or SETDB1 expression is associated with the hot tumor immune microenvironment in patients with cancer. A, Bubble plot showing multiple GSEA of the indicated pathways in a pan-cancer analysis of the TCGA dataset. NES >0: The gene set is enriched in ATF7IP low–expressing cancer samples (bottom 25%) compared with ATF7IP high–expressing cancer samples (top 25%). B, Bubble plot showing multiple GSEA of the indicated pathways in a pan-cancer analysis of the TCGA dataset. NES >0: The gene set is enriched in SETDB1 low–expressing cancer samples (bottom 25%) compared with SETDB1 high–expressing cancer samples (top 25%). — Low ATFIP or SETDB1 expression is associated with the hot tumor immune microenvironment in patients with cancer. A, Bubble plot showing multiple GSEA of the indicated pathways in a pan-cancer analysis of the TCGA dataset. NES >0: The gene set is enriched in ATF7IP low–expressing cancer samples (bottom 25%) compared with ATF7IP high–expressing cancer samples (top 25%). B, Bubble plot showing multiple GSEA of the indicated pathways in a pan-cancer analysis of the TCGA dataset. NES >0: The gene set is enriched in SETDB1 low–expressing cancer samples (bottom 25%) compared with SETDB1 high–expressing cancer samples (top 25%).